Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis
- PMID: 22710578
- DOI: 10.1038/ajg.2012.179
Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis
Abstract
Objectives: Clostridium difficile-associated diarrhea (CDAD) is a major cause of morbidity and increasing health-care costs among hospitalized patients. Although exposure to antibiotics remains the most documented risk factor for CDAD, attention has recently been directed toward a plausible link with proton pump inhibitors (PPIs). However, the results of studies on the association between CDAD and PPIs remain controversial. We have conducted a meta-analysis to summarize the association between PPIs and CDAD among hospitalized patients.
Methods: A systematic search of published literature on studies that investigated the association between PPIs and CDAD from 1990 to 2010 was conducted on Medline and PubMed. The identified articles were reviewed for additional references. The most adjusted risk estimates were extracted by two authors and summarized using random effects meta-analysis. We also conducted a subgroup analysis by study design. Publication bias was evaluated using the Begg and Egger tests. A sensitivity analysis using the Duval and Tweedie "trim-and-fill" method has also been performed.
Results: Twenty-three studies including close to 300,000 patients met the inclusion criteria. There was a 65% (summary risk estimate 1.69 with a 95% confidence interval (CI) from 1.395 to 1.974; P<0.000) increase in the incidence of CDAD among patients on PPIs. By study design, whether case-control study (17) or cohort study (6), there was still a significant increase in the incidence of CDAD among PPI users. The risk estimates were 2.31 (95% CI from 1.72 to 3.10; P<0.001) and 1.48 (95% CI from 1.25 to 1.75; P<0.001) for cohort and case-control studies, respectively.
Conclusions: There is sufficient evidence to suggest that PPIs increase the incidence of CDAD. Our meta-analysis shows a 65% increase in the incidence of CDAD among PPI users. We recommend that the routine use of PPIs for gastric ulcer prophylaxis should be more prudent. Establishing a guideline for the use of PPI may help in the future with the judicious use of PPIs. Further studies, preferably prospective, are needed to fully explore the association between PPIs and CDAD.
Comment in
-
How much do PPIs contribute to C. difficile infections?Am J Gastroenterol. 2012 Jul;107(7):1020-1. doi: 10.1038/ajg.2012.174. Am J Gastroenterol. 2012. PMID: 22764024
-
Risk of Clostridium difficile infection with acid-suppressive therapy; pitfalls in accurate estimation.Am J Gastroenterol. 2013 Feb;108(2):277-8. doi: 10.1038/ajg.2012.394. Am J Gastroenterol. 2013. PMID: 23381074 No abstract available.
-
Does confounding explain the association between PPIs and Clostridium difficile-related diarrhea?Am J Gastroenterol. 2013 Feb;108(2):278-9. doi: 10.1038/ajg.2012.395. Am J Gastroenterol. 2013. PMID: 23381076 No abstract available.
-
Response to Freedberg and Abrams.Am J Gastroenterol. 2013 Feb;108(2):279. doi: 10.1038/ajg.2012.399. Am J Gastroenterol. 2013. PMID: 23381078 No abstract available.
Similar articles
-
Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score.J Clin Gastroenterol. 2012 May-Jun;46(5):397-400. doi: 10.1097/MCG.0b013e3182431d78. J Clin Gastroenterol. 2012. PMID: 22298089
-
Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients.Am J Gastroenterol. 2008 Sep;103(9):2308-13. doi: 10.1111/j.1572-0241.2008.01975.x. Epub 2008 Aug 12. Am J Gastroenterol. 2008. PMID: 18702653
-
Proton-pump inhibitors and the risk of Clostridium difficile-associated diarrhea in high-risk antibiotics users: A population-based case-crossover study.Pharmacoepidemiol Drug Saf. 2019 Apr;28(4):479-488. doi: 10.1002/pds.4745. Epub 2019 Mar 8. Pharmacoepidemiol Drug Saf. 2019. PMID: 30848536
-
Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis.World J Gastroenterol. 2017 Sep 21;23(35):6500-6515. doi: 10.3748/wjg.v23.i35.6500. World J Gastroenterol. 2017. PMID: 29085200 Free PMC article. Review.
-
Proton pump inhibitors and risk for Clostridium difficile associated diarrhea.Biomed J. 2014 Jul-Aug;37(4):178-83. doi: 10.4103/2319-4170.128002. Biomed J. 2014. PMID: 25116712 Review.
Cited by
-
Seizure and Takotsubo Cardiomyopathy Due to Proton Pump Inhibitor.J Community Hosp Intern Med Perspect. 2024 Jul 2;14(4):114-117. doi: 10.55729/2000-9666.1360. eCollection 2024. J Community Hosp Intern Med Perspect. 2024. PMID: 39391120 Free PMC article.
-
Impact of Helicobacter pylori Eradication on Inflammatory Bowel Disease Onset and Disease Activity: To Eradicate or Not to Eradicate?Diseases. 2024 Aug 8;12(8):179. doi: 10.3390/diseases12080179. Diseases. 2024. PMID: 39195178 Free PMC article. Review.
-
Bibliometrics and knowledge mapping of the pathogenesis of hepatic encephalopathy in patients with liver cirrhosis.Heliyon. 2024 Jul 16;10(15):e34330. doi: 10.1016/j.heliyon.2024.e34330. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39145014 Free PMC article.
-
Vonoprazan-associated Clostridioides difficile infection: an analysis of the Japanese Adverse Drug Event Report and the FDA Adverse Event Reporting System.Ther Adv Drug Saf. 2024 Jul 31;15:20420986241260211. doi: 10.1177/20420986241260211. eCollection 2024. Ther Adv Drug Saf. 2024. PMID: 39091466 Free PMC article.
-
Physicians' perceptions and awareness of adverse effects of proton pump inhibitors and impact on prescribing patterns.Front Pharmacol. 2024 Jun 26;15:1383698. doi: 10.3389/fphar.2024.1383698. eCollection 2024. Front Pharmacol. 2024. PMID: 38989150 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
